Zymeworks Inc.

ZYMENASDAQ • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
24.15 USD
↗ 0.38 (1.60%)AT CLOSE (11:59 AM EDT)
24.42
↗ 0.27 (1.14%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
24.42
↗ 0.27 (1.14%)
🔴Market: CLOSED

ZYME is currently priced at $24.15. ZYME shows a split signal: technical indicators suggest "Strong Buy" while underlying fundamentals indicate "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jun 26, 2026.

Open?$23.75
High?$24.40
Low?$23.52
Prev. Close?$23.77
Volume?942.3K
Avg. Volume?687.0K
VWAP?$23.90
Rel. Volume?1.37x
Bid / Ask
Bid?$20.45 × 100
Ask?$28.62 × 100
Spread?$8.17
Midpoint?$24.54
Valuation & Ratios
Market Cap?1.8B
Shares Out?73.0M
Float?46.0M
Float %?62.3%
P/E Ratio?N/A
P/B Ratio?10.86
EPS?-$1.40
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Themes
Healthcare - Oncology›Targeted Therapy & Precision OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
264
Market Cap
1.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.zymeworks.com
Listed
2017-04-28
Address
108 PATRIOT DRIVE, SUITE A
MIDDLETOWN, DE 19709
Phone: 302-274-8744
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
6
Momentum?
3
Short Sent.?
40
Piotroski F-Score?2/9Weak
Altman Z-Score?0.51Distress
Confidence?68%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?9.76%Elevated
Short Interest?4.5M
Days to Cover?5.6
Free Float46.0M
Avg Daily Volume804.7K
Settlement Date2026-06-15
Financial Health
Current Ratio?10.82Strong
Quick Ratio?10.82Strong
Cash Ratio?6.85Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A▾
P/B?
Peers
100
S&P
18
10.86HIGH▾
P/S?
Peers
100
S&P
3
21.86HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-14.2CHEAP▾
EV/Sales?
Peers
100
S&P
3
18.86HIGH▾
Returns & Efficiency
ROE?
S&P
3
-62.7%WEAK▾
ROA?
S&P
3
-21.5%WEAK▾
Cash Flow & Enterprise
FCF?$-77037000
Enterprise Value?$1.5B
Fundamentals ratios updated end of day
MarketsMoversWatchlist